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Abstract
Summary: High-throughput screening (HTS) enables systematic testing of thousands of chemical compounds for
potential use as investigational and therapeutic agents. HTS experiments are often conducted in multi-well plates
that inherently bear technical and experimental sources of error. Thus, HTS data processing requires the use of ro-
bust quality control procedures before analysis and interpretation. Here, we have implemented an open-source ana-
lysis application, Breeze, an integrated quality control and data analysis application for HTS data. Furthermore,
Breeze enables a reliable way to identify individual drug sensitivity and resistance patterns in cell lines or patient-
derived samples for functional precision medicine applications. The Breeze application provides a complete solution
for data quality assessment, dose–response curve fitting and quantification of the drug responses along with inter-
active visualization of the results.
Availability and implementation: The Breeze application with video tutorial and technical documentation is access-
ible at https://breeze.fimm.fi; the R source code is publicly available at https://github.com/potdarswapnil/Breeze
under GNU General Public License v3.0.
Contact: swapnil.potdar@helsinki.fi
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Advances in automated liquid dispensing, assay miniaturization, sys-
tems biology as well as ex vivo disease models have boosted the de-
velopment of high-throughput cell-based functional testing
platforms. Thousands of conventional cell lines have been screened
with hundreds of compounds in several large-scale projects, such as
the Cancer Cell Line Encyclopedia (Barretina et al., 2012),
Genomics of Drug Sensitivity in Cancer (Yang et al., 2013), Cancer
Therapeutics Response Portal (Seashore-Ludlow et al., 2015) and
Genentech Cell Line Screening Initiative (Haverty et al., 2016).
Similar drug testing efforts have been applied on primary cell models
to generate individualized drug profiles for drug repurposing, pa-
tient stratification and for the identification of potential drug combi-
nations (Kodack et al., 2017; Lee et al., 2018; Pemovska et al.,
2013, 2015; Saeed et al., 2017). One common end-point in cell-
based drug testing is cell viability and/or toxicity readouts generated
over multiple concentrations in microwell plates (96-, 384- and
1536-well formats), where plate layout and placement of controls
play an important role to minimize the risk of experimental errors
influencing data quality (Mpindi et al., 2015). Therefore, quality
control (QC) process is required to ensure compliant and reprodu-
cible drug testing readouts from the assay. The dose–response curve-
fitting process enables direct translation of the raw cell viability
measurements based on several intensity scoring technologies to
clinically interpretable dose values. The fitted dose–response curve is
then used to summarize and quantify the observed response into a
single metric, such as IC50 and EC50 dose or as an absolute area
under the curve (AUC) or drug sensitivity score (DSS; Yadav et al.,
2015). To date, there are several, freely available analysis tools
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available for handling the drug screening data, such as cellHTS
(https://www.dkfz.de/signaling/cellHTS/) (Boutros et al., 2006),
HTS Navigator (Fourches et al., 2014), Knime (https://knime.com),
PharmacoGx (Smirnov et al., 2016) as well as commercial solutions
such as Dotmatics (https://dotmatics.com) and Genedata Screener
(https://genedata.com). Although these are useful resources for drug
testing data analysis, we believe there is a room for improvement in
the alignment of the data flow process through QC, dose–response
curve fitting, multiparametric scoring and interactive visualizations.
Breeze is an easy to use publicly available tool, which includes
comprehensive plate QC statistics with a diverse collection of drug
quantification metrics and interactive visualization options, which
offers the users the ability to perform comparison of drug response
profiles across multiple samples (Fig. 1). Systematic use of
standardized data quality processing and drug quantification
methods enables direct comparison of responses from a large
number of studies (Mpindi et al., 2016).
2 Materials and methods
2.1 Data submission and processing
The Breeze application allows multiple data input formats, which
need to comprise of drug names, concentration ranges and pheno-
typic measurements. These measurements can both be provided as
raw data or pre-calculated percent inhibition (PI) values. In case,
when the raw data are provided, PI for each data point is calculated
based on the values of positive and negative controls on the corre-
sponding plate. Detailed description of input data format is given in
technical documentation. A template of the data input structure is
available for download to facilitate data processing and analysis.
2.2 Quality control
Common technical errors in HTS assays include spatial plate vari-
ability and/or striping due to dispensing errors as well as edge effects
due to uneven evaporation of the plate edges. Hence, assessing and
quantifying the potential errors of the raw data is a crucial first step
of the analysis. The standard QC metrics Z’ (Zhang, 1999) and
SSMD (Zhang, 2007) explore the distribution of the positive and
negative control wells (Chen et al., 2016). However, those metrics
may not capture all spatial plate effects and hence Breeze generates a
comprehensive table of different metrics along with several visual-
izations. The QC table includes parameters such as Z’, SSMD, sig-
nal/background ratio, SD, coefficient of variation and central
tendency of controls (Supplementary Fig. S1). The QC visualizations
in Breeze include interactive plate heatmaps (Supplementary Fig.
S3), scatterplots and barplots (Fig. 1A and Supplementary Figs S1,
S2 and S4–S6).Visualizations are helpful in interpretation and spot-
ting technical problems such as issues in dispensing cells, drugs,
reagents on culture conditions, edge effects, striping, patterning as
well as observing signal window, performance, and distribution of
compounds and controls, variations across plates and outliers.
2.3 Curve fitting
Curve fitting is an important part of the dose–response data analysis
and involves arranging the PI values at each point of the concentra-
tion range and fitting these points using four-parameter logistic
curve (Findlay and Dillard, 2007; Vølund, 1978). In order to quan-
tify the quality of curve fitting, a standard error of the estimate is
calculated for each dose–response curve. The resulting curve fit
images (Fig. 1B, top-right) and the fitting parameters are exported in
the Excel files.
2.4 Quantification of drug responses
Breeze offers several possibilities to summarize dose–response rela-
tionship into a single metric including IC50, EC50, AUC and DSS.
The DSS scoring metric is adding normalization to standard AUC
(Yadav et al., 2015). This standardization facilitates the correlation
of drug sensitivity and resistance testing results across several stud-
ies. The results are depicted by interactive visualizations such as
heatmaps and bar plots (Fig. 1B and Supplementary Fig. S7). The
heatmap provides a comprehensive overview of the data based on
distance matrix methods such as Pearson, Euclidean, Manhattan,
Spearman and so on. The bar plots list the top-responding drugs in a
sample (Supplementary Fig. S8), while the circular tree correlates
drug response patterns among group of samples (Supplementary Fig.
S9). The user can also upload the DSS of the reference/control
screen, to calculate differential response of drugs, between samples
and control.
2.5 Tutorial and feedback
Breeze is implemented using R and PHP and hosted with Apache
HTTP Server. To facilitate its usage, a step-by-step video tutorial
and example input data are available on the website. The user may
leave their comments or suggestions using a feedback form. Breeze
source code is provided at https://github.com/potdarswapnil/Breeze,
to run analyses independently and potentially extend functionality.
3 Conclusion
The Breeze application facilitates a quick and robust analysis of
drug testing data by integrating systematic QC procedures and drug
response quantification to a standard metric that enables method
comparison across several studies. The interactive visualizations, in-
tuitive graphics and easily exportable results provide a framework
for reproducible and quality processing of drug testing data. Breeze
is a unique computational environment, which provides extensive
Fig. 1. Example outcome plots of Breeze application. (A) The technical quality is
visualized by listing QC metrics such as Z’ and SSMD, along with bar plots, plate
heat maps and scatterplot of signal intensities of plate wells help in identifying dis-
tribution of controls and pinpoint outliers. (B) Drug quantification visualization in
form of interactive heatmap and circular plots. The heatmap shows efficacies of the
drugs (higher in red and lower in white) across different samples along with drug
names and potential drug targets. Hovering over the heatmap shows individual
dose–response curves of specific drugs
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functionality in terms of QC, summary metrics and visualization of
different aspects of HTS experiments.
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